Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRANDYWINE REALTY TRUSTBDN · Entity 5445 | Director | May 28, 2026 | June 01, 2026 |
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | July 01, 2026 | July 06, 2026 |
| UNIVERSAL DISPLAY CORP \PA\OLED · Entity 4078 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRANDYWINE REALTY TRUST
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 121,445 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 37,582 · Balance 121,445 F1: These shares reflect the $115,000 Annual Trustee award, the number of shares of which is calculated based upon a closing price on 05/28/26 of $3.06. Shares vested immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares reflect the $115,000 Annual Trustee award, the number of shares of which is calculated based upon a closing price on 05/28/26 of $3.06. Shares vested immediately upon grant.
ROCKWELL MEDICAL, INC.
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,944 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 9,633 · Balance 20,944 F1: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting. F2: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting.
F2: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split.
UNIVERSAL DISPLAY CORP \PA\
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,771 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 455 · Balance 3,771 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Renovacor, Inc.
Report date December 01, 2022 · Filed December 06, 2022
Section 16 reporting ended · disclosed 2022-12-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Expires 2031-09-03 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-01 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F2: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 455 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-412202 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,771 Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:25 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 9,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-047125 · wk-form4_1783344355.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,944 F1 · kind: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting. F2 · balance_after: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 455 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-294433 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,316 Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 14:31 UTC | BRANDYWINE REALTY TRUST BDN · Entity 5445 | GrantCommon Shares of Beneficial Interest | 37,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-250245 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,445 F1 · shares: These shares reflect the $115,000 Annual Trustee award, the number of shares of which is calculated based upon a closing price on 05/28/26 of $3.06. Shares vested immediately upon grant. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 456 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-140016 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,861 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002344 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,405 Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-228263 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,064 Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-092918 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,723 Read SEC document |
| May 21, 2025 Filed May 23, 2025 13:01 UTC | BRANDYWINE REALTY TRUST BDN · Entity 5445 | GrantCommon Shares of Beneficial Interest | 27,644 | $4.16 | $114,999.04 |
DisclosureSEC source: 0000950170-25-076655 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,863 F1 · security: These shares reflect the $115,000 Annual Trustee award, the number of shares of which is calculated based upon a closing price on 05/21/25 of $4.16. Shares vested immediately upon grant. Read SEC document |
| May 20, 2025 Filed May 21, 2025 23:10 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051716 · tm2515860-3_4seq1.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,111 F1 · kind: Restricted stock units vest on May 20, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049268 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,381 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 314 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001086 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,039 Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 314 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111396 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725 Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 314 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-080408 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411 Read SEC document |
| May 23, 2024 Filed May 28, 2024 21:24 UTC | BRANDYWINE REALTY TRUST BDN · Entity 5445 | GrantCommon Shares of Beneficial Interest | 25,054 | $4.59 | $114,997.86 |
DisclosureSEC source: 0000950170-24-065384 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,219 F1 · security: These shares reflect the $115,000 Annual Trustee share award, the number of shares of which is calculated based upon a closing price on 05/23/24 of $4.59. Shares vested immediately upon grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:07 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 36,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-064813 · tm2415466-4_4seq1.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,111 F1 · kind: Restricted stock units vest on May 21, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:00 UTC | UNIVERSAL DISPLAY CORP \PA\ OLED · Entity 4078 | GrantCommon Stock | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040106 · ownership.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97 Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 10:17 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001104659-23-109742 · tm2328668-3_4seq1.xml · derivative · entry 2 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-10-16 F2 · derivative.exercise_date: Stock options vest on October 16, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 10:17 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109742 · tm2328668-3_4seq1.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · kind: Restricted stock units vest on October 16, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 16, 2023 Filed Feb 6, 2024 23:56 UTC Amendment | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001104659-24-011215 · tm245360-2_4aseq1.xml · derivative · entry 2 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-10-16 F2 · derivative.exercise_date: Stock options vest on October 16, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 16, 2023 Filed Feb 6, 2024 23:56 UTC Amendment | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-011215 · tm245360-2_4aseq1.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 F1 · kind: Restricted stock units vest on October 16, 2024, subject to the Reporting Person's continued service to the Issuer. F3 · balance_after: This Form 4 Amendment is being filed solely to report 2,000 shares that were inadvertently omitted from the Form 4 filed by the Reporting Person on October 18, 2023. Read SEC document |
| May 25, 2023 Filed May 26, 2023 15:23 UTC | BRANDYWINE REALTY TRUST BDN · Entity 5445 | GrantCommon Shares of Beneficial Interest | 31,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032381 · doc4.xml · nonDerivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,165 F1 · security: These shares reflect the $115,000 Annual Trustee share award, the number of shares of which is calculated based upon a closing price on 05/25/2023 of $3.69. Shares vested immediately upon grant. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:23 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023387 · form4.xml · derivative · entry 2 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-05-25 F1 · derivative.exercise_price: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:23 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023387 · form4.xml · derivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2031-09-03 F1 · derivative.exercise_price: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:05 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantStock Option · Derivative | 12,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001062993-22-013700 · form4.xml · derivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests on the earlier of (a) May 25, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 23:04 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantOption · Derivative | 24,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001192482-21-000717 · edgar.xml · derivative · entry 1 Lau Joan · CIK 0001881621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-09-03 F1 · derivative.exercise_date: The stock options will vest and become exercisable 25% on the first anniversary of the grant and the remainder will vest and become exercisable in 36 equal monthly installments on the 3rd of each month for the remaining 36 months, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.